|
DE10347710B4
(de)
|
2003-10-14 |
2006-03-30 |
Johannes-Gutenberg-Universität Mainz |
Rekombinante Impfstoffe und deren Verwendung
|
|
DE102005046490A1
(de)
|
2005-09-28 |
2007-03-29 |
Johannes-Gutenberg-Universität Mainz |
Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
|
|
US9732131B2
(en)
|
2006-02-27 |
2017-08-15 |
Calviri, Inc. |
Identification and use of novopeptides for the treatment of cancer
|
|
EP3101122B1
(en)
|
2009-08-24 |
2023-06-14 |
Baylor College of Medicine |
Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
|
|
BR112012029066A2
(pt)
*
|
2010-05-14 |
2020-09-01 |
The General Hospital Corporation |
composições e processos de identificação de neoantígenos específicos de tumor.
|
|
HRP20211595T1
(hr)
|
2011-05-24 |
2022-01-21 |
BioNTech SE |
Individualizirana cjepiva protiv raka
|
|
HRP20191535T1
(hr)
*
|
2011-05-24 |
2019-11-29 |
Biontech Rna Pharmaceuticals Gmbh |
Individualizirana cjepiva protiv raka
|
|
EP2757153B1
(en)
*
|
2011-08-02 |
2019-07-03 |
The University of Tokyo |
Method for assessing myelodysplastic syndrome or myeloid tumor predisposition, polypeptide and antibody therefor, and candidate screening method for therapeutic drug or prophylactic drug therefor
|
|
US20130164746A1
(en)
*
|
2011-09-29 |
2013-06-27 |
Davide Rossi |
Mutations in SF3B1 and Chronic Lymphocytic Leukemia
|
|
WO2013086464A1
(en)
*
|
2011-12-07 |
2013-06-13 |
The Broad Institute, Inc. |
Markers associated with chronic lymphocytic leukemia prognosis and progression
|
|
GB201121308D0
(en)
|
2011-12-12 |
2012-01-25 |
Cell Medica Ltd |
Process
|
|
PT2812431T
(pt)
|
2012-02-09 |
2019-10-18 |
Baylor College Medicine |
Pepmixes para gerar ctls multivirais com larga especifidade
|
|
WO2013143555A1
(en)
|
2012-03-26 |
2013-10-03 |
Biontech Ag |
Rna formulation for immunotherapy
|
|
AU2013266066A1
(en)
|
2012-05-25 |
2014-12-11 |
Agenus Inc. |
Identification of MHC class I phospho-peptide antigens from breast cancer utilizing sHLA technology and complementary enrichment strategies
|
|
CA2879024A1
(en)
*
|
2012-07-12 |
2014-01-16 |
Persimmune, Inc. |
Personalized cancer vaccines and adoptive immune cell therapies
|
|
GB201214007D0
(en)
*
|
2012-08-07 |
2012-09-19 |
Scancell Ltd |
Anti-tumour immune responses to modified self-epitopes
|
|
EP3718556A3
(en)
|
2012-08-31 |
2020-12-30 |
University Of Virginia Patent Foundation |
Target peptides for immunotherapy and diagnostics
|
|
EP4088737A3
(en)
|
2012-09-05 |
2023-02-08 |
University Of Virginia Patent Foundation |
Target peptides for colorectal cancer therapy and diagnostics
|
|
US10501801B2
(en)
|
2012-09-28 |
2019-12-10 |
University Of Connecticut |
Identification of tumor-protective epitopes for the treatment of cancers
|
|
WO2014082729A1
(en)
|
2012-11-28 |
2014-06-05 |
Biontech Ag |
Individualized vaccines for cancer
|
|
GB2508414A
(en)
*
|
2012-11-30 |
2014-06-04 |
Max Delbrueck Centrum |
Tumour specific T cell receptors (TCRs)
|
|
RU2718988C2
(ru)
|
2013-02-22 |
2020-04-15 |
Куревак Аг |
Комбинация противораковой рнк-вакцины и ингибитора пути pd-1 и ее применение
|
|
EP2958588B1
(en)
|
2013-02-22 |
2017-08-23 |
CureVac AG |
Combination of vaccination and inhibition of the pd-1 pathway
|
|
EP2970907B1
(en)
|
2013-03-14 |
2020-01-01 |
The Johns Hopkins University |
Nanoscale artificial antigen presenting cells
|
|
CN118750591A
(zh)
*
|
2013-04-07 |
2024-10-11 |
博德研究所 |
用于个性化瘤形成疫苗的组合物和方法
|
|
WO2014180490A1
(en)
|
2013-05-10 |
2014-11-13 |
Biontech Ag |
Predicting immunogenicity of t cell epitopes
|
|
US10023626B2
(en)
|
2013-09-30 |
2018-07-17 |
Modernatx, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
WO2015077717A1
(en)
|
2013-11-25 |
2015-05-28 |
The Broad Institute Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
|
|
WO2015085147A1
(en)
|
2013-12-05 |
2015-06-11 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
|
US20160310584A1
(en)
*
|
2013-12-06 |
2016-10-27 |
The Broad Institute Inc. |
Formulations for neoplasia vaccines
|
|
EP3082853A2
(en)
*
|
2013-12-20 |
2016-10-26 |
The Broad Institute, Inc. |
Combination therapy with neoantigen vaccine
|
|
PE20161344A1
(es)
*
|
2014-01-02 |
2016-12-23 |
Memorial Sloan Kettering Cancer Center |
Determinantes de respuesta del cancer a la inmunoterapia
|
|
WO2015135558A1
(en)
|
2014-03-12 |
2015-09-17 |
Curevac Gmbh |
Combination of vaccination and ox40 agonists
|
|
CA2945816A1
(en)
|
2014-04-15 |
2015-10-22 |
University Of Virginia Patent Foundation |
Isolated t cell receptors and methods of use therefor
|
|
US11338026B2
(en)
|
2014-09-10 |
2022-05-24 |
The University Of Connecticut |
Identification of immunologically protective neo-epitopes for the treatment of cancers
|
|
WO2016040110A1
(en)
*
|
2014-09-10 |
2016-03-17 |
The University Of Connecticut |
Identification of immunologically protective neo-epitopes for the treatment of cancers
|
|
EP3194970B1
(en)
*
|
2014-09-10 |
2021-07-28 |
F. Hoffmann-La Roche AG |
Immunogenic mutant peptide screening platform
|
|
EP3193892A4
(en)
*
|
2014-09-14 |
2018-09-12 |
Washington University |
Personalized cancer vaccines and methods therefor
|
|
PL3193917T3
(pl)
*
|
2014-09-17 |
2022-01-17 |
Io Biotech Aps |
Kompozycje szczepionek zawierające 2,3-dioksygenazę tryptofanową lub jej fragmenty
|
|
CN107002038B
(zh)
*
|
2014-09-17 |
2021-10-15 |
约翰·霍普金斯大学 |
用于识别、富集和/或扩增抗原特异性t细胞的试剂和方法
|
|
WO2016045732A1
(en)
|
2014-09-25 |
2016-03-31 |
Biontech Rna Pharmaceuticals Gmbh |
Stable formulations of lipids and liposomes
|
|
US10973894B2
(en)
|
2014-10-02 |
2021-04-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human |
Methods of isolating T cells having antigenic specificity for a cancer-specific mutation
|
|
JP6991857B2
(ja)
*
|
2014-10-10 |
2022-01-13 |
イデラ ファーマシューティカルズ インコーポレイテッド |
Ｔｌｒ９アゴニストをチェックポイント阻害剤と共に用いるがんの治療
|
|
MA40737A
(fr)
|
2014-11-21 |
2017-07-04 |
Memorial Sloan Kettering Cancer Center |
Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
|
|
US10993997B2
(en)
*
|
2014-12-19 |
2021-05-04 |
The Broad Institute, Inc. |
Methods for profiling the t cell repertoire
|
|
US10975442B2
(en)
|
2014-12-19 |
2021-04-13 |
Massachusetts Institute Of Technology |
Molecular biomarkers for cancer immunotherapy
|
|
WO2016128060A1
(en)
*
|
2015-02-12 |
2016-08-18 |
Biontech Ag |
Predicting t cell epitopes useful for vaccination
|
|
WO2016154544A1
(en)
*
|
2015-03-25 |
2016-09-29 |
The Regents Of The University Of Michigan |
Compositions and methods for delivery of biomacromolecule agents
|
|
US20190099475A1
(en)
*
|
2015-04-08 |
2019-04-04 |
Nantomics, Llc |
Cancer neoepitopes
|
|
CA2988388C
(en)
|
2015-04-23 |
2022-11-22 |
Nantomics, Llc |
Cancer neoepitopes
|
|
GB201507030D0
(en)
|
2015-04-24 |
2015-06-10 |
Immatics Biotechnologies Gmbh |
Immunotherapy against lung cancers, in particular NSCLC
|
|
CN107750278B
(zh)
*
|
2015-04-27 |
2023-10-03 |
癌症研究技术有限公司 |
治疗癌症的方法
|
|
US10544392B2
(en)
|
2015-05-01 |
2020-01-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
|
|
SG10201912485PA
(en)
|
2015-05-13 |
2020-02-27 |
Agenus Inc |
Vaccines for treatment and prevention of cancer
|
|
TW202523682A
(zh)
*
|
2015-05-20 |
2025-06-16 |
美商博德研究所有限公司 |
共有之gata3相關之腫瘤特異性新抗原
|
|
TW202241500A
(zh)
*
|
2015-06-09 |
2022-11-01 |
美商博德研究所有限公司 |
用於贅瘤疫苗之調配物及其製備方法
|
|
EP3323070B1
(en)
*
|
2015-07-14 |
2024-05-08 |
Personal Genome Diagnostics Inc. |
Neoantigen analysis
|
|
WO2017020026A1
(en)
*
|
2015-07-30 |
2017-02-02 |
Modernatx, Inc. |
Concatemeric peptide epitopes rnas
|
|
GB201516047D0
(en)
|
2015-09-10 |
2015-10-28 |
Cancer Rec Tech Ltd |
Method
|
|
JP6999941B2
(ja)
|
2015-09-18 |
2022-02-10 |
ベイラー カレッジ オブ メディスン |
病原体からの免疫原性抗原同定および臨床的有効性との相関
|
|
WO2017059902A1
(en)
|
2015-10-07 |
2017-04-13 |
Biontech Rna Pharmaceuticals Gmbh |
3' utr sequences for stabilization of rna
|
|
AU2016339924B2
(en)
*
|
2015-10-12 |
2020-01-02 |
Nantomics, Llc |
Compositions and methods for viral cancer neoepitopes
|
|
CA3003251A1
(en)
*
|
2015-10-12 |
2017-04-20 |
Nantomics, Llc |
Systems, compositions, and methods for discovery of msi and neoepitopes that predict sensitivity to checkpoint inhibitors
|
|
AU2016339022B2
(en)
*
|
2015-10-12 |
2020-09-10 |
Nantomics, Llc |
Iterative discovery of neoepitopes and adaptive immunotherapy and methods therefor
|
|
US10339274B2
(en)
*
|
2015-10-12 |
2019-07-02 |
Nantomics, Llc |
Viral neoepitopes and uses thereof
|
|
EP3364949A4
(en)
|
2015-10-22 |
2019-07-31 |
ModernaTX, Inc. |
CANCER VACCINES
|
|
KR102771841B1
(ko)
|
2015-11-06 |
2025-02-24 |
벤타나 메디컬 시스템즈, 인코포레이티드 |
대표 진단법
|
|
TWI733719B
(zh)
|
2015-12-07 |
2021-07-21 |
美商河谷控股Ｉｐ有限責任公司 |
改善的組合物及用於新表位之病毒遞送的方法及其應用
|
|
RU2729116C2
(ru)
*
|
2015-12-16 |
2020-08-04 |
Гритстоун Онколоджи, Инк. |
Идентификация, производство и применение неоантигенов
|
|
JP2019502753A
(ja)
*
|
2015-12-23 |
2019-01-31 |
ムーンショット ファーマ エルエルシー |
ナンセンス変異依存ｍＲＮＡ分解機構の抑制による免疫応答の誘導法
|
|
JP2019505512A
(ja)
|
2016-01-08 |
2019-02-28 |
バッシボディ アクスイェ セルスカプ |
治療用抗癌ネオエピトープワクチン
|
|
US20170224796A1
(en)
|
2016-02-05 |
2017-08-10 |
Xeme Biopharma Inc. |
Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery System
|
|
CA3014252A1
(en)
*
|
2016-02-12 |
2017-08-17 |
Nantomics, Llc |
High-throughput identification of patient-specific neoepitopes as therapeutic targets for cancer immunotherapies
|
|
CN105720176A
(zh)
*
|
2016-02-19 |
2016-06-29 |
京东方科技集团股份有限公司 |
一种胶囊量子点和发光二极管、制备方法及显示装置
|
|
US11585805B2
(en)
|
2016-02-19 |
2023-02-21 |
Nantcell, Inc. |
Methods of immunogenic modulation
|
|
JP2019513021A
(ja)
*
|
2016-03-24 |
2019-05-23 |
ナントセル，インコーポレイテッド |
ネオエピトープ提示のための配列の配置および配列
|
|
CA3056212A1
(en)
*
|
2016-04-07 |
2017-10-12 |
Bostongene Corporation |
Construction and methods of use of a therapeutic cancer vaccine library comprising fusion-specific vaccines
|
|
WO2017180769A1
(en)
*
|
2016-04-13 |
2017-10-19 |
Capten Therapeutics Inc. |
Small molecules for immunogenic treatment of cancer
|
|
US12257352B2
(en)
|
2016-06-20 |
2025-03-25 |
The Regents Of The University Of Michigan |
Compositions and methods for delivery of biomacromolecule agents
|
|
WO2018005276A1
(en)
*
|
2016-06-29 |
2018-01-04 |
The Johns Hopkins University |
Neoantigens as targets for immunotherapy
|
|
CN115404196A
(zh)
|
2016-07-13 |
2022-11-29 |
哈佛学院院长等 |
抗原呈递细胞模拟支架及其制备和使用方法
|
|
PT3488443T
(pt)
*
|
2016-07-20 |
2021-09-24 |
BioNTech SE |
Seleção de neoepítopos como alvos específicos da doença para terapia com eficácia melhorada
|
|
CA3032688A1
(en)
*
|
2016-08-02 |
2018-02-08 |
Nantcell, Inc. |
Transfection of dendritic cells and methods therefor
|
|
WO2018045249A1
(en)
*
|
2016-08-31 |
2018-03-08 |
Medgenome, Inc. |
Methods to analyze genetic alterations in cancer to identify therapeutic peptide vaccines and kits therefore
|
|
US10350280B2
(en)
|
2016-08-31 |
2019-07-16 |
Medgenome Inc. |
Methods to analyze genetic alterations in cancer to identify therapeutic peptide vaccines and kits therefore
|
|
JP7200093B2
(ja)
|
2016-09-15 |
2023-01-06 |
アイデラ・ファーマシューティカルズ，インコーポレーテッド |
がん治療用ｔｌｒ９アゴニストを用いた免疫調節
|
|
US11976299B2
(en)
|
2016-09-23 |
2024-05-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of preparing an isolated population of dendritic cells and methods of treating cancer using same
|
|
WO2018071796A2
(en)
*
|
2016-10-13 |
2018-04-19 |
The Johns Hopkins University |
Compositions and methods for identifying functional anti-tumor t cell responses
|
|
JP7181862B2
(ja)
*
|
2016-10-18 |
2022-12-01 |
リージェンツ オブ ザ ユニバーシティ オブ ミネソタ |
腫瘍浸潤リンパ球および治療の方法
|
|
US20190321481A1
(en)
|
2016-11-11 |
2019-10-24 |
Nantbio, Inc. |
Immunomodulatory compositions, processes for making the same, and methods for inhibiting cytokine storms
|
|
CA3045811A1
(en)
|
2016-12-01 |
2018-06-07 |
Nantomics, Llc |
Tumor antigenicity processing and presentation
|
|
WO2018140391A1
(en)
|
2017-01-24 |
2018-08-02 |
The Broad Institute, Inc. |
Compositions and methods for detecting a mutant variant of a polynucleotide
|
|
EP3576751A4
(en)
*
|
2017-02-01 |
2021-08-04 |
ModernaTX, Inc. |
RNA ANTI-CANCER VACCINES
|
|
JP2020514321A
(ja)
*
|
2017-02-01 |
2020-05-21 |
モデルナティーエックス， インコーポレイテッド |
活性化がん遺伝子変異ペプチドをコードする免疫調節治療ｍＲＮＡ組成物
|
|
KR20190142767A
(ko)
|
2017-03-20 |
2019-12-27 |
제노세아 바이오사이언스, 인코퍼레이티드 |
치료 방법
|
|
WO2018183544A1
(en)
*
|
2017-03-31 |
2018-10-04 |
Dana-Farber Cancer Institute, Inc. |
Method for identification of retained intron tumor neoantigens from patient transcriptome
|
|
US12303561B2
(en)
|
2017-04-03 |
2025-05-20 |
Biontech Us Inc. |
Protein antigens and uses thereof
|
|
WO2018187515A1
(en)
|
2017-04-04 |
2018-10-11 |
Avidea Technologies, Inc. |
Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
|
|
KR102841050B1
(ko)
*
|
2017-04-19 |
2025-08-01 |
그릿스톤 바이오, 인코포레이티드 |
신생항원 동정, 제조, 및 용도
|
|
IL314202B1
(en)
|
2017-04-24 |
2026-04-01 |
Nantcell Inc |
Neoepitope vectors and methods for them
|
|
MX2019013259A
(es)
|
2017-05-08 |
2020-01-13 |
Gritstone Oncology Inc |
Vectores de neoantigeno de alfavirus.
|
|
EP3622068B1
(en)
|
2017-05-10 |
2024-02-28 |
The Broad Institute, Inc. |
Methods for determination of mutations in single replication events
|
|
EP3622092A4
(en)
|
2017-05-11 |
2021-06-23 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS OF USE OF CD8 + TUMOR-INFILTRATING LYMPHOCYTE SUBTYPES AND GENE SIGNATURES THEREOF
|
|
US20200276285A1
(en)
*
|
2017-06-02 |
2020-09-03 |
Arizona Board Of Regents On Behalf Of Arizona State University |
A method to create personalized cancer vaccines
|
|
WO2018224166A1
(en)
|
2017-06-09 |
2018-12-13 |
Biontech Rna Pharmaceuticals Gmbh |
Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
|
|
KR20240113607A
(ko)
*
|
2017-06-21 |
2024-07-22 |
트랜스진 |
개인 맞춤형 백신
|
|
US12049643B2
(en)
|
2017-07-14 |
2024-07-30 |
The Broad Institute, Inc. |
Methods and compositions for modulating cytotoxic lymphocyte activity
|
|
TWI832820B
(zh)
|
2017-07-21 |
2024-02-21 |
美商伯克利之光生命科技公司 |
抗原呈現合成表面、共價功能化表面、經活化之t細胞及其用途
|
|
CN111727262A
(zh)
|
2017-07-25 |
2020-09-29 |
加州理工学院 |
胞啃介导的表位发现
|
|
WO2019036043A2
(en)
*
|
2017-08-16 |
2019-02-21 |
Medgenome Inc. |
METHOD FOR GENERATING A COCKTAIL OF PERSONALIZED ANTICANCER VACCINES FROM TUMOR DERIVED GENETIC MODIFICATIONS FOR THE TREATMENT OF CANCER
|
|
US12025615B2
(en)
|
2017-09-15 |
2024-07-02 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Methods of classifying response to immunotherapy for cancer
|
|
WO2019070769A1
(en)
*
|
2017-10-02 |
2019-04-11 |
Curematch, Inc. |
METHOD FOR PREDICTING ANTIGENICITY AND / OR IMMUNOGENICITY OF A TUMOR DERIVED NEO-PEPTIDE USING MUTATIONAL SIGNATURE PATTERNS
|
|
RU2020115161A
(ru)
*
|
2017-10-06 |
2021-11-08 |
Дзе Уистар Инститьют Оф Энэтоми Энд Байолоджи |
Днк моноклональных антител против ctla-4 для лечения и профилактики рака
|
|
KR20260039788A
(ko)
*
|
2017-10-10 |
2026-03-20 |
시애틀 프로젝트 코포레이션 |
핫스팟을 이용한 신생항원 동정
|
|
CN111801415A
(zh)
*
|
2017-11-06 |
2020-10-20 |
路德维格癌症研究院 |
扩增淋巴细胞的方法
|
|
EP3706770A4
(en)
*
|
2017-11-07 |
2021-10-27 |
Nektar Therapeutics |
IMMUNOTHERAPEUTIC COMBINATION FOR THE TREATMENT OF CANCER
|
|
CA3081840A1
(en)
|
2017-11-08 |
2019-05-16 |
Neon Therapeutics, Inc. |
T cell manufacturing compositions and methods
|
|
CA3083097A1
(en)
|
2017-11-22 |
2019-05-31 |
Gritstone Oncology, Inc. |
Reducing junction epitope presentation for neoantigens
|
|
CN109682978B
(zh)
*
|
2017-11-30 |
2020-07-03 |
四川康德赛医疗科技有限公司 |
一种肿瘤突变肽mhc亲和力预测方法及其应用
|
|
US11793867B2
(en)
|
2017-12-18 |
2023-10-24 |
Biontech Us Inc. |
Neoantigens and uses thereof
|
|
EP3735271A4
(en)
|
2018-01-04 |
2022-06-15 |
Iconic Therapeutics, Inc. |
ANTI-TISSUE FACTOR ANTIBODIES, ANTIBODY DRUG CONJUGATES AND RELATED METHODS
|
|
WO2019147925A1
(en)
|
2018-01-26 |
2019-08-01 |
Nantcell, Inc. |
Compositions and methods for combination cancer vaccine and immunologic adjuvant therapy
|
|
WO2019147921A1
(en)
|
2018-01-26 |
2019-08-01 |
Nantcell, Inc. |
Rapid verification of virus particle production for a personalized vaccine
|
|
CN108491689B
(zh)
*
|
2018-02-01 |
2019-07-09 |
杭州纽安津生物科技有限公司 |
基于转录组的肿瘤新抗原鉴定方法
|
|
CN119851752A
(zh)
*
|
2018-02-27 |
2025-04-18 |
磨石生物公司 |
利用泛等位基因模型进行的新抗原鉴别
|
|
MA52363A
(fr)
|
2018-04-26 |
2021-03-03 |
Agenus Inc |
Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation
|
|
CN112368386A
(zh)
|
2018-05-23 |
2021-02-12 |
磨石肿瘤生物技术公司 |
共有抗原
|
|
US12528848B2
(en)
|
2018-05-25 |
2026-01-20 |
The Wistar Institute Of Anatomy And Biology |
Tumor-specific neoantigens and methods of using the same
|
|
WO2019241315A1
(en)
|
2018-06-12 |
2019-12-19 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
BR112020025764A2
(pt)
|
2018-06-19 |
2021-05-11 |
Biontech Us Inc. |
neoantígenos e usos dos mesmos
|
|
CA3106574A1
(en)
|
2018-07-26 |
2020-01-30 |
Frame Pharmaceuticals B.V. |
Arid1a, cdkn2a, kmt2b, kmt2d, tp53 and pten vaccines for cancer
|
|
WO2020022901A1
(en)
|
2018-07-26 |
2020-01-30 |
Frame Pharmaceuticals B.V. |
Cancer vaccines for uterine cancer
|
|
EP3827263A1
(en)
|
2018-07-26 |
2021-06-02 |
Frame Pharmaceuticals B.V. |
Cancer vaccines for colorectal cancer
|
|
CA3106567A1
(en)
|
2018-07-26 |
2020-01-30 |
Frame Pharmaceuticals B.V. |
Cancer vaccines for kidney cancer
|
|
CA3106562A1
(en)
*
|
2018-07-26 |
2020-01-30 |
Frame Pharmaceuticals B.V. |
Off-the-shelf cancer vaccines
|
|
WO2020022899A1
(en)
|
2018-07-26 |
2020-01-30 |
Frame Pharmaceuticals B.V. |
Cancer vaccines for breast cancer
|
|
CN109021062B
(zh)
*
|
2018-08-06 |
2021-08-20 |
倍而达药业（苏州）有限公司 |
一种肿瘤新抗原的筛选方法
|
|
JP7539367B2
(ja)
|
2018-08-31 |
2024-08-23 |
ガーダント ヘルス， インコーポレイテッド |
無細胞ｄｎａにおけるマイクロサテライト不安定性の検出
|
|
GB201815041D0
(en)
|
2018-09-14 |
2018-10-31 |
Scancell Ltd |
Epitopes
|
|
US11945850B2
(en)
|
2018-09-17 |
2024-04-02 |
Immatics Biotechnologies Gmbh |
B*44 restricted peptides for use in immunotherapy against cancers and related methods
|
|
CA3112813A1
(en)
|
2018-09-21 |
2020-03-26 |
Berkeley Lights, Inc. |
Functionalized well plate, methods of preparation and use thereof
|
|
CN112771214B
(zh)
|
2018-09-27 |
2025-06-13 |
耐考德治疗股份有限公司 |
用于选择新表位的方法
|
|
JP2022512714A
(ja)
|
2018-10-18 |
2022-02-07 |
バークレー ライツ，インコーポレイテッド |
プロト抗原提示合成表面、活性化ｔ細胞及びそれらの使用
|
|
AU2019375997A1
(en)
|
2018-11-08 |
2021-06-03 |
Neximmune, Inc. |
T cell compositions with improved phenotypic properties
|
|
WO2020131586A2
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
|
CN109706065A
(zh)
*
|
2018-12-29 |
2019-05-03 |
深圳裕策生物科技有限公司 |
肿瘤新生抗原负荷检测装置及存储介质
|
|
SG11202109073VA
(en)
|
2019-02-20 |
2021-09-29 |
Rubius Therapeutics Inc |
Engineered erythroid cells including loadable antigen-presenting polypeptides and methods of use
|
|
CN111621564B
(zh)
*
|
2019-02-28 |
2022-03-25 |
武汉大学 |
一种鉴定有效肿瘤新抗原的方法
|
|
US12427195B1
(en)
*
|
2019-03-11 |
2025-09-30 |
La Jolla Institute For Immunology |
Methods of neoantigen identification
|
|
WO2020185010A1
(ko)
*
|
2019-03-12 |
2020-09-17 |
(주)신테카바이오 |
인공지능모델기반 분자동역학 빅데이터를 활용한 신생항원 면역치료정보 제공 시스템 및 방법
|
|
EP3963335B1
(en)
*
|
2019-05-03 |
2024-08-21 |
Epivax Therapeutics, Inc. |
Neoantigens in cancer
|
|
EP3966323A4
(en)
*
|
2019-05-06 |
2024-04-24 |
The Regents Of The University Of Michigan |
TARGETED THERAPY
|
|
MX2021014525A
(es)
|
2019-05-30 |
2022-03-17 |
Gritstone Bio Inc |
Adenovirus modificados.
|
|
CN112011833B
(zh)
*
|
2019-05-30 |
2024-04-26 |
上海桀蒙生物技术有限公司 |
筛选和分离肿瘤新生抗原的方法
|
|
CN110322925B
(zh)
*
|
2019-07-18 |
2021-09-03 |
杭州纽安津生物科技有限公司 |
一种预测融合基因产生新生抗原的方法
|
|
CN110706747B
(zh)
*
|
2019-09-17 |
2021-09-07 |
北京橡鑫生物科技有限公司 |
检测肿瘤新生抗原多肽的方法和装置
|
|
EP4038222A4
(en)
|
2019-10-02 |
2023-10-18 |
Arizona Board of Regents on behalf of Arizona State University |
Methods and compositions for identifying neoantigens for use in treating and preventing cancer
|
|
US11920202B2
(en)
|
2020-04-09 |
2024-03-05 |
University Of Connecticut |
Unbiased identification of tumor rejection mediating neoepitopes
|
|
WO2021228999A1
(en)
*
|
2020-05-12 |
2021-11-18 |
Institut Curie |
Neoantigenic epitopes associated with sf3b1 mutations
|
|
WO2021230247A1
(ja)
*
|
2020-05-12 |
2021-11-18 |
大日本住友製薬株式会社 |
癌を処置するための医薬組成物
|
|
WO2021252904A1
(en)
|
2020-06-11 |
2021-12-16 |
Massachusetts Institute Of Technology |
Ribonucleoprotein approach to boost the sting signaling for cancer immunotherapy
|
|
KR20230046313A
(ko)
|
2020-08-06 |
2023-04-05 |
그릿스톤 바이오, 인코포레이티드 |
다중에피토프 백신 카세트
|
|
US20230374455A1
(en)
|
2020-08-13 |
2023-11-23 |
Biontech Us Inc. |
T cell manufacturing compositions and methods
|
|
GB2613718A
(en)
*
|
2020-08-31 |
2023-06-14 |
World Biotech Regenerative Medical Group Ltd |
Personalized immunogenic compositions and methods for producing and using same
|
|
KR102552632B1
(ko)
*
|
2020-11-06 |
2023-07-06 |
사회복지법인 삼성생명공익재단 |
중추신경계 림프종을 진단하기 위한 마커, 이를 포함하는 중추신경계 림프종 진단 키트 및 중추신경계 림프종을 진단하는 방법
|
|
EP4313129A4
(en)
*
|
2021-03-26 |
2025-05-14 |
The Translational Genomics Research Institute |
METHODS AND COMPOUNDS FOR NEOANTIGEN VACCINES
|
|
EP4330380A1
(en)
|
2021-04-30 |
2024-03-06 |
Tigen Pharma SA |
Single vessel expansion of lymphocytes
|
|
CN117813108A
(zh)
*
|
2021-05-27 |
2024-04-02 |
亚马逊科技公司 |
基于肽的新抗原疫苗的多组分化学组合物
|
|
JP2024534120A
(ja)
|
2021-08-24 |
2024-09-18 |
ビオンテック・ソシエタス・エウロパエア |
インビトロ転写技術
|
|
CN115772564B
(zh)
*
|
2021-09-08 |
2023-08-18 |
广州市基准医疗有限责任公司 |
用于辅助检测肺癌体细胞atm基因融合突变的甲基化生物标记物及其应用
|
|
EP4419716A1
(en)
|
2021-10-21 |
2024-08-28 |
CureVac Netherlands B.V. |
Cancer neoantigens
|
|
CN116287158A
(zh)
*
|
2021-12-08 |
2023-06-23 |
初源海生物科技(深圳)有限公司 |
一种新抗原鉴定和疗效预测方法
|
|
WO2023177655A1
(en)
|
2022-03-14 |
2023-09-21 |
Generation Bio Co. |
Heterologous prime boost vaccine compositions and methods of use
|
|
WO2024077256A1
(en)
|
2022-10-07 |
2024-04-11 |
The General Hospital Corporation |
Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
|
|
WO2024083345A1
(en)
|
2022-10-21 |
2024-04-25 |
BioNTech SE |
Methods and uses associated with liquid compositions
|
|
JP2025541604A
(ja)
|
2022-11-02 |
2025-12-22 |
ティゲン・ファーマ・ソシエテ・アノニム |
リンパ球の拡大
|
|
US12531162B1
(en)
*
|
2023-05-31 |
2026-01-20 |
Northeastern University |
Multi-dimensional phenotypic space for genotype to phenotype mapping and intelligent design of cancer drug therapies using a deep learning net
|
|
EP4474016A1
(en)
|
2023-06-07 |
2024-12-11 |
Julius-Maximilians-Universität Würzburg |
Strategies to target extracellularly accessible ras protein
|
|
WO2024261339A1
(en)
|
2023-06-23 |
2024-12-26 |
Tigen Pharma Sa |
Lymphocyte-stimulatory matrix (lsm) and uses thereof for expansion of lymphocyte populations
|
|
US12562256B2
(en)
*
|
2023-11-07 |
2026-02-24 |
New York University |
Systems, methods and computer-accessible medium for identifying target pairs for CAR-T therapy
|
|
WO2025202937A1
(en)
|
2024-03-26 |
2025-10-02 |
BioNTech SE |
Cancer vaccines
|